Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Chemotherapy-induced Neutropenia × Docetaxel × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 112 Breast Neoplasms 111 Prostatic Neoplasms 79 Lung Neoplasms 37 Neoplasms 27 Squamous Cell Carcinoma of Head and Neck 26 Neoplasm Metastasis 25 Stomach Neoplasms 22 Esophageal Neoplasms 20 Head and Neck Neoplasms 19 Pancreatic Neoplasms 16 Ovarian Neoplasms 15 Parkinson Disease 4, Autosomal Dominant Lewy Body 14 Urinary Bladder Neoplasms 12 Sarcoma 10 Triple Negative Breast Neoplasms 8 Carcinoma, Transitional Cell 8 Fallopian Tube Neoplasms 7 Carcinoma, Ovarian Epithelial 7 Adenocarcinoma of Lung 7 Adenocarcinoma Of Esophagus 7 Recurrence 6 Carcinoma, Squamous Cell 5 Carcinoma 5 Inflammatory Breast Neoplasms 4 Esophageal Squamous Cell Carcinoma 4 Breast Neoplasms, Male 4 Advanced Solid Tumors 4 Adenocarcinoma 4 Urethral Neoplasms 3

Interventions

pegfilgrastim 4 balugrastim 2 NPI 2358 2 Granulocyte Colony-Stimulating Factor 2 Drug Therapy 2 Doxorubicin 1 Docetaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01126190 2023-03-28

NEUGR-003

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 3 Completed

381 enrolled 13 charts

Chemotherapy-induced Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡